Proteinuria following administration of immune check point inhibitor: a case-control observational study
Proteinuria could develop during the course of ICIs-therapy. Urinalysis should be monitored, especially for patients received multi-cycle of ICIs-administration and comorbid with liver cirrhosis.
Authors
- Pengwei Chen (ORCID: https://orcid.org/0000-0001-5886-3034)
- Zhuofei Bi (ORCID: https://orcid.org/0000-0001-8914-4446)
- Ziqing Gao
- Jianan Su
- Qiongqiong Yang (ORCID: https://orcid.org/0000-0001-5489-2209)
- Min Feng (ORCID: https://orcid.org/0000-0001-5024-0537)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1186/s12882-024-03868-5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Traditional Chinese Medicine Bureau of Guangdong Province